ValiRx focus on the treatment of cancer, specialising in epigenomic and genetic analysis. Our technologies and products however can also be applied to other fields as well, such as neurology and inflammatory diseases.
The Company listed on the Alternative Investment Market ("AIM") of the London Stock Exchange in October 2006 and is focused on creating a portfolio of innovative products through investment in specific development projects. We actively manage projects within this portfolio as a trading company and are not an investment vehicle.
Satu Vainikka, from Valirx, talks about the unlimited potential of GeneICE
Thursday, May 19, 2011
Dr Satu Vainikka, CEO at Valirx (LON:VAL), tells Proactive Investors that there is tremendous potential for its GeneICE programme Satu believes that the recently raised £3.3mln will see Valirx through to pre-clinical studies at which point it is likely that a commercial joint venture partner will be found within the sector.
No investment advice
The Company is a publisher and is not registered with or authorised by the Financial Services Authority (FSA). You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
